Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Components

Components at other companies

Exelixis logo
ExelixisEXEL
——

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.62B+226%

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's components.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's components?
Arcus Biosciences (RCUS) reported components of 100 in Q1 2026.
How has Arcus Biosciences's components changed year-over-year?
Arcus Biosciences's components increased by 40.8% year-over-year, from 71 to 100.
What is the long-term trend for Arcus Biosciences's components?
Over 3 years (2022 to 2025), Arcus Biosciences's components has grown at a -47.9% compound annual growth rate (CAGR), from 219 to 31.
What does components mean?
This represents a granular breakdown or specific sub-category of a larger financial statement line item. It is used to provide transparency into the composition of complex balance sheet or income statement accounts. Investors analyze these components to understand the underlying drivers of specific financial performance metrics.